India has approved two vaccines against the Covid-19 diseases. Covidshield and Covaxin are the vaccines manufactured by Indian pharmaceutical companies such as the Serum Institute of India (Covishield) and Bharat Biotech International Limited (Covaxin). India is the largest vaccine producer country in the world. As of April 2021, India had exported around 864.5 million doses of vaccines to 85 countries and also 10.5 million vaccine doses gifted to 45 countries through the Government of India.
Indian Vaccine Manufacturer Companies
Serum Institute of India (SII)
Serum Institute of India is an Indian Biotechnological and Pharmaceutical Company. It is situated in Pune, Maharashtra, India, and was Founded by Cyrus Poonawalla in 1966. The SII is the world’s largest vaccine manufacturer.
Covishield Oxford-AstraZeneca Vaccine
The SII has a partner with British Swedish pharmaceutical company AstraZeneca. It developed the AZD1222 vaccine in partnership with Oxford University. SII is the manufacturer of Oxford-AstraZeneca Vaccine and is approved by Oxford University.
In December 2020, the SII got emergency approval for the vaccine development with AstraZeneca. The Oxford AstraZeneca vaccine is sold in India under the brand name Covishield. Its Covid-19 Vaccine is used to protect against the infection by the SARS-cov2 virus and prevents Covid-19 in adults aged 18 years and older.
The Covishield efficiency is 76% to prevent covid-19 beginning at 22 days of the first dose and 81.3% efficient after the 2nd dose of vaccine. The vaccine has been approved by several medicine agencies worldwide, such as WHO (World Health Organisation), European Medicine Agencies (EMA), and Therapeutic Goods Administration by Australia.
Covishield Vaccine Price
The serum institute of India SII to price the Covidsheild vaccine for the state government at Rs. 400 per dose and 600 per dose for private hospitals. As per the latest update, Adar Poonawalla changed the vaccine price to Rs 300 from Rs 400 per dose for state hospitals with effective immediately.
- Pain or tenderness at the injection site.
- Headache, Tiredness, Muscle or Joints Aches, Fever, Chills, Nausea.
Bharat Biotech International Limited
Bharat Biotech International Limited is an Indian Biotechnological Company and its headquarter is located in Hyderabad, India. It engaged in drug development, drug Discovery, Vaccine Manufacturing, and Health Core Production.
Bharat Biotech announced they have partnered with US-based Company FluGen and the University of Wisconsin Madison to develop a Covid-19 Vaccine. In May 2020, ICMR and the National Institute of Virology approved and gave the virus strain sample for developing a fully indigenous Covid-19 Vaccine. They got permission to conduct Phase 1 and 2 clinical trials in India for the developed covid-19 vaccine. The Bharat Biotech Vaccine was developed under the brand name (B13V152) Covaxin and approved by the DGCI (Drug General Controller of India).
As of March 2021, the state interim efficiency rate of the Covaxin phase trial is 81%. The SARS-Cov Variant B.1.1.7 and B.1.617 (double mutant) was identified in the UK, the Covaxin showed promising results in neutralizing against the new strain.
Covaxin Vaccine Price
The indigenous covid-19 Covaxin price is Rs. 600 per dose for state governments and Rs. 1200 per dose for a private hospital. it is also available for the central government at the rate of 150 per dose.
- Injection site pain, Swelling.
- Swelling of your face and throat.
- Rash all over the body.
- Dizziness and weaknesses.
- Body Acha, Fever, Headache, Nausea
Zydus Cadila Covid Vaccine
India’s second homegrown ( made in India ) Covid-19 Vaccine developed by zydus Cadila under the brand name of Zycov-D. In July 2020, Zydus got permission to conduct Phase 1,2, and 3 human trials of developed vaccines from the DCGI Govt. Of India. The Cadila applies for emergency use authorization ( EUA ) of Zycov-D. It is currently under the phase 3 efficacy trial, after EUA approval by the regulator it’s will become the 4th vaccine against the coronavirus in India.
Zycov-D is a DNA vaccine, it works against the major viral membrane of the protein of Novak coronavirus. The vaccine is based on Plasmid DNA technology and developed at their Vaccine Technology centre in Ahmedabad.
Zydus Cadila submits all efficacy data of the vaccine to the Drug Controller General of India, at the end of this month. The company plans to manufacture 240 million doses of Zycov-D vaccine I’m this year.